Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Bromocriptine/cabergoline

Treatment failure

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kreitschmann-Andermahr I, et al. Significant Response to Temozolomide in Two Aggressively Growing Pituitary Adenomas. Journal of the Endocrine Society 4 (Suppl.): A606, May 2020. Available from: URL: https://dx.doi.org/10.1210/jendso/bvaa046.1196 [abstract] Kreitschmann-Andermahr I, et al. Significant Response to Temozolomide in Two Aggressively Growing Pituitary Adenomas. Journal of the Endocrine Society 4 (Suppl.): A606, May 2020. Available from: URL: https://dx.doi.org/10.1210/jendso/bvaa046.1196 [abstract]
Metadaten
Titel
Bromocriptine/cabergoline
Treatment failure
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-50352-7

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Ibrutinib